European Journal of Cancer Supplements This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Optimal approach for renal cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Cora N. Sternberg (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

The seventh tumour–node–metastasis staging system for lung cancer: Sequel or prequel?
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Jan P. van Meerbeeck , Annelies Janssens Anatomical cancer extent is an important predictor of prognosis and determines treatment choices. In non-small-cell lung cancer (NSCLC) the tumour–node–metastasis (TNM) classification developed by Pierre Denoix replaced in 1968 the Veterans Administration Lung cancer Group (VALG) classification, which was still in use for small-cell lung cancer (SCLC). Clifton Mountain suggested several improvements based on a database of mostly surgically treated United States (US...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Prognostic factors in resected lung carcinomas
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Keith M. Kerr , Marianne C. Nicolson (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Adjuvant chemotherapy of non-small-cell lung cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): J.Y. Douillard (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Cecile Le Péchoux , Olaf Mercier , Deborah Belemsagha , Ryan Bouaita , Benjamin Besse , Elie Fadel Most long-term survivors of non-small-cell lung cancer (NSCLC) are patients who have had a completely resected tumour. However, this is only achievable in about 30% of the patients. Even in this highly selected group of patients, there is still a high risk of both local and distant failure. Adjuvant treatments such as chemotherapy (CT) and radiotherapy (RT) have therefore been evaluated in order to improve ...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Surgical treatment of early-stage non-small-cell lung cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Paul E. Van Schil , Bram Balduyck , Michèle De Waele , Jeroen M. Hendriks , Marjan Hertoghs , Patrick Lauwers Surgical resection remains the standard of care for functionally operable early-stage non-small-cell lung cancer (NSCLC) and resectable stage IIIA disease. The role of invasive staging and restaging techniques is currently being debated, but they provide the largest biopsy samples which allow for precise mediastinal staging. Different types of operative procedures are currently available to the t...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Optimal approach for upfront resectable non-small-cell lung cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Jan P. van Meerbeeck (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Adjuvant therapy for high-risk melanoma
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Alexander M.M. Eggermont (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Immunotherapy of melanoma
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): John B.A.G. Haanen Melanoma is considered one of the immunogenic – if not the most immunogenic – malignancies. This is based on several observations. 1. Spontaneous remissions occur occasionally. 2. In about 5% of melanomas no primary tumour is found. The genetic aberrations of these tumours closely resemble those of cutaneous melanomas, and therefore are suggestive of spontaneous regressions of the primary tumours. 3. Both primary tumours and metastases often have brisk lymphocytic infiltrates, a phe...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Simone M. Goldinger , Carla Murer , Pascale Stieger , Reinhard Dummer Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and molecular features, including targetable mutations in several kinases such as BRAF or c-KIT. The successful development of therapies targeting these mutations has resulted in new specific treatment options. These include vemurafenib, dabrafenib, trametinib, imatinib and other kinase inhibitors that are selected when the respective mutation...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Melanoma epidemiology, biology and prognosis
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Z. Ali , N. Yousaf , J. Larkin (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Optimal approach for melanoma
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Martin Gore (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Adjuvant chemotherapy
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): B. Glimelius (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

The modern anatomical surgical approach to localised rectal cancer
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): R.G. Orsini , T. Wiggers , M.C. DeRuiter , P. Quirke , R.G. Beets-Tan , C.J. van de Velde , H.J.T. Rutten (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Neoadjuvant therapy before surgical treatment
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Rob Glynne-Jones , Ian Chau Neoadjuvant treatment in terms of preoperative radiotherapy reduces local recurrence in rectal cancer, but this improvement has little if any impact on overall survival. Currently performed optimal quality-controlled total mesorectal excision (TME) surgery for patients in the trial setting can be associated with very low local recurrence rates of less than 10% whether the patients receive radiotherapy or not. Hence metastatic disease is now the predominant issue. The concept of neo...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research